Skip to main content
SpringerLink
Log in

A case of thyroiditis during natalizumab therapy for multiple sclerosis

  • Letter to the Editor
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Marriott JJ, O’Connor PW. Emerging therapies in relapsing-remitting multiple sclerosis. Rev Recent Clin Trials 2010, 5: 179–88.

    Article  CAS  PubMed  Google Scholar 

  2. Rudick RA, Panzara MA. Natalizumab for the treatment of relapsing multiple sclerosis. Biologics 2008, 2: 189–99.

    CAS  PubMed Central  PubMed  Google Scholar 

  3. Iaffaldano P, D’Onghia M, Trojano M. Safety profile of tysabri: international risk management plan. Neurol Sci 2009, 30(Suppl 2): S159–62.

    PubMed  Google Scholar 

  4. Durelli L, Ferrero B, Oggero A, et al. Thyroid function and autoimmunity during interferon beta-1b treatment: a multicenter prospective study. J Clin Endocrinol Metab 2001, 86: 3525–32.

    CAS  PubMed  Google Scholar 

  5. Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biologic therapy. EurJ Endocrinol 2011, 164: 303–7.

    Article  CAS  Google Scholar 

  6. Minagar A, Alexander JS, Sahraian MA, Zivadinov R. Alemtuzumab and multiple sclerosis: therapeutic application. Expert Opin Biol Ther 2010, 10: 421–9.

    Article  PubMed  Google Scholar 

  7. Tamaskar I, Bukowski R, Elson P et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 2008, 19: 265–8.

    Article  CAS  PubMed  Google Scholar 

  8. Grossmann M, Premaratne E, Desai J, Davis ID. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 2008, 9: 669–72.

    Article  Google Scholar 

  9. Makita N, Miyakawa M, Fujita T, Iiri T. Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid 2010, 20: 323–6.

    Article  CAS  PubMed  Google Scholar 

  10. Mannavola D, Coco P, Vannucchi G, et al. A novel tyrosine kinase selective inhibitor, sunitinib induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007, 92: 3531–4.

    Article  CAS  PubMed  Google Scholar 

  11. Wong E, Rosen LS, Mulay M, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007, 17: 351–5.

    Article  CAS  PubMed  Google Scholar 

  12. Tomer Y, Menconi F Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab 2009, 23: 703–12.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology and Medical Science, University of Genova, Genoa, Italy

    S. Oddo & M. Giusti

  2. Department of Neuroscience, Ophtalmology and Genetics, University of Genova, Genoa, Italy

    A. Laroni & A. Uccelli

Authors
  1. S. Oddo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Laroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Uccelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Giusti
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oddo, S., Laroni, A., Uccelli, A. et al. A case of thyroiditis during natalizumab therapy for multiple sclerosis. J Endocrinol Invest 34, 408–409 (2011). https://doi.org/10.1007/BF03347466

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03347466

Keywords

Search

Navigation